



## Medicine: dostarlimab (brand name: Jemperli®)

GlaxoSmithKline

The Scottish Medicines Consortium (SMC) has assessed dostarlimab for treating adults with endometrial cancer that is advanced or has come back, and has got worse despite treatment with platinum-containing chemotherapy. It is used where the cancer cells have certain genetic changes that mean the cancer can be called microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). This document summarises the SMC decision and what it means for patients.

### What has SMC said?

After careful consideration, SMC has accepted dostarlimab on an interim basis (interim acceptance) for the treatment of endometrial cancer as described above. Interim acceptance is an option available to SMC for certain\* medicines. In this case, the clinical evidence in the company submission was based on a single-arm clinical trial, which means there is no comparison with placebo or another treatment, leading to uncertainty in the evidence for decision making. An interim acceptance means that dostarlimab is accepted for use subject to ongoing evaluation and reassessment once further evidence is available.

This advice takes into account a confidential discount offered by the pharmaceutical company that improves the cost-effectiveness of dostarlimab.

### What does SMC's decision mean for patients?

The decision to accept dostarlimab on an interim basis means that if your healthcare professional thinks that it is the right medicine for you, you should be able to have the treatment on the NHS in Scotland. Once further evidence is available, SMC will reassess the medicine and provide an updated decision on its routine availability in NHSScotland.



### What is dostarlimab used for?

Dostarlimab is used to treat endometrial cancer where the cancer is advanced or has come back, and has got worse despite treatment with platinum-containing chemotherapy. Endometrial cancer is a type of cancer found in the lining of the womb (the endometrium). When endometrial cancer is advanced, it has spread outside the womb to nearby organs (such as the ovaries), or to organs further away in the body. Dostarlimab is for patients where the cancer is MSI-H or dMMR (these

\*<https://www.scottishmedicines.org.uk/how-we-decide/interim-acceptance-decision-option/>

genetic changes can be identified by a test using a biopsy). Currently treatment options for these patients are very limited.

## How does dostarlimab work?

Dostarlimab is an immunotherapy. This is a type of cancer treatment that stimulates the immune system (the body's natural defence system) to fight the cancer. Some cancer cells produce proteins that switch off immune cells. Dostarlimab attaches to a protein called PD-1 on the immune cells, which stops the cancer switching them off, and helps the immune system fight the cancer.

## How does SMC make its decision?

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland.

To do this SMC considers the following:

- Evidence from the company about how well the medicine works compared with current treatments available in Scotland, in relation to how much they will cost to buy and administer.
- Information from patient groups about the potential impact of the medicine on patients and carers.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.

When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not only those who may be treated with the medicine under consideration.

You can find more detailed information about the SMC assessment of dostarlimab by looking at the SMC Detailed Advice Document (SMC2404).

## More information

The organisation below can provide more information and support for people with endometrial cancer and their families. SMC is not responsible for the content of any information provided by external organisations.

### GO Girls



<https://www.gogirlssupport.org>



01305 255719

You can find out more about dostarlimab (Jemperli®) in the Patient Leaflet by searching for the medicine name on the electronic medicines compendium (EMC) website.



<https://www.medicines.org.uk/emc/>